BLISS GVS PHARMA LTD.

Bliss GVS Pharma Limited announced a significant change in its promoter status. Following a share purchase agreement and completion of an open offer, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have acquired control and are now classified as the new Promoters. Consequently, the erstwhile Promoters and Promoter Group have been reclassified to the 'Public' category as per SEBI Regulations 31A(10). This change was noted by the Board of Directors on September 28, 2026.

Catalyst Trusteeship Limited, acting as Debenture Trustee on behalf of debenture holders, has disclosed the pledge of 5,09,84,595 equity shares of Bliss GVS Pharma Ltd. This represents 47.95% of the total share capital and 46.77% of the total diluted share capital. The pledge was made on September 30, 2026. This disclosure is made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bliss GVS Pharma Ltd's Board of Directors, at its meeting on October 01, 2026, approved the adoption of two new Employee Stock Option Policies (ESOPs): the Senior Executive Employee Stock Option Policy 2026 and the Employee Stock Option Policy 2026. These policies, subject to shareholder and regulatory approvals, facilitate the grant of stock options to employees. Under the Senior Executive ESOP 2026, up to 26,50,000 equity shares (approximately 2.49% of fully diluted paid-up capital) can be granted at a discounted fixed exercise price of ₹10 per share, with a minimum one-year vesting period. The Employee ESOP 2026 allows for the grant of up to 47,00,000 equity shares. The total options granted under both policies amount to 73,50,000 equity shares.

Anupam Rasayan India Limited, along with its Person Acting in Concert (PAC), Mates Visa Consultancy Private Limited, has acquired a substantial stake in Bliss GVS Pharma Limited. The acquisition, made pursuant to a Share Purchase Agreement, has resulted in Anupam Rasayan India and its PAC holding 50.07% of the total share capital of Bliss GVS Pharma. Prior to this acquisition, their combined holding was 2.12%. The transaction involved the acquisition of 5,09,84,595 equity shares, representing 47.95% of the total voting capital. The total equity share capital of Bliss GVS Pharma considered for this acquisition was 10,63,30,472 shares as of September 28, 2026. This move signifies a significant change in the shareholding structure of Bliss GVS Pharma.

Bliss GVS Pharma Ltd has announced the closure of its trading window effective Thursday, October 01, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut for designated persons, insiders, and their immediate relatives until 48 hours after the announcement of the unaudited financial results for the quarter and half-year ended September 30, 2026. The exact date for the board meeting to declare these results will be intimated later. Insiders are advised against trading in the company's securities during this period.

Bliss GVS Pharma Ltd announced the outcome of its Board Meeting held on September 28, 2026. The meeting confirmed the change in control and promoter status, with Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited (PAC) collectively acquiring 47.95% of the equity share capital. This acquisition makes them the new promoters of the company. Additionally, the board approved the appointment of Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat as Additional Directors. The resignation of Mr. Narsimha Shibroor Kamath from the position of Managing Director was also noted. A postal ballot notice for the appointment of the new directors was approved.

Bliss GVS Pharma Limited's board of directors has acknowledged the re-classification of its erstwhile promoters and promoter group members to the 'public' category. This change follows the consummation of a share purchase agreement and an open offer, leading to a change in the company's control. The re-classification is in accordance with Regulation 31A(10) of the SEBI Listing Regulations. Several individuals and entities previously classified as promoters now hold minimal or no shares, shifting their status to public shareholders.

Bliss GVS Pharma Ltd has announced that its Board of Directors will convene on October 1, 2026. The meeting, to be held via video conferencing, will primarily focus on considering and approving the establishment of two new employee stock option plans: the Senior Executive Employee Stock Option Plan 2026 and the Employee Stock Option Plan 2026. This strategic move aims to incentivize and retain key personnel by offering them equity participation in the company's growth.

Bliss GVS Pharma Ltd announced a significant change in control following the acquisition of 47.95% equity shares by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited. This transaction, completed on September 28, 2026, makes Anupam Rasayan and Mates Visa the new promoters. Concurrently, the board approved the appointment of three new Non-Executive Non-Independent Directors: Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat. The company also noted the resignation of Mr. Narsimha Shibroor Kamath as Managing Director.

SBI Capital Markets Ltd, acting as the Manager to the Open Offer, has submitted a Post-Offer Advertisement for Bliss GVS Pharma Limited to the BSE. This advertisement, dated August 31, 2026, and published on September 1, 2026, details the open offer made by Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited (PAC), to acquire up to 2,77,26,848 equity shares, representing 26.00% of the expanded voting share capital. The offer was made to eligible public shareholders of Bliss GVS Pharma Limited in compliance with SEBI (SAST) Regulations, 2011. The advertisement appeared in The Financial Express (English), Jansatta (Hindi), and Navshakti (Marathi).